Elagolix sodium salt (CAS number 832720-36-2, 1, Figure 1) is the first non-peptide orally active gonadotropin-releasing hormone receptor antagonist (GnRHR-ant), approved since 2018 by FDA for the management of moderate-to-severe endometriosis-associated pain [1] and, more recently, against the symptoms related to uterine fibroids [2]. The gene discussed is GNRHR; the disease is endometriosis.